Last reviewed · How we verify
Benzoyl peroxide with clindamycin and doxycycline
Benzoyl peroxide with clindamycin and doxycycline, marketed by Stiefel, a GSK Company, is a combination therapy for acne with a well-established presence in the market. The key strength of this product lies in its dual-action mechanism, combining the antibacterial effects of clindamycin and doxycycline with the keratolytic and antimicrobial properties of benzoyl peroxide. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Benzoyl peroxide with clindamycin and doxycycline |
|---|---|
| Also known as | Acne |
| Sponsor | Stiefel, a GSK Company |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: